481 related articles for article (PubMed ID: 9663807)
1. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
Miners JO; Birkett DJ
Br J Clin Pharmacol; 1998 Jun; 45(6):525-38. PubMed ID: 9663807
[TBL] [Abstract][Full Text] [Related]
2. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
4. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
7. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
[TBL] [Abstract][Full Text] [Related]
8. Allelic and functional variability of cytochrome P4502C9.
Bhasker CR; Miners JO; Coulter S; Birkett DJ
Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
10. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
11. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
Miners JO; Coulter S; Birkett DJ; Goldstein JA
Pharmacogenetics; 2000 Apr; 10(3):267-70. PubMed ID: 10803683
[No Abstract] [Full Text] [Related]
12. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
13. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of the human cytochrome P450 CYP2C9 locus.
Stubbins MJ; Harries LW; Smith G; Tarbit MH; Wolf CR
Pharmacogenetics; 1996 Oct; 6(5):429-39. PubMed ID: 8946475
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
[TBL] [Abstract][Full Text] [Related]
18. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K
Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997
[TBL] [Abstract][Full Text] [Related]
20. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.
Rettie AE; Haining RL; Bajpai M; Levy RH
Epilepsy Res; 1999 Jul; 35(3):253-5. PubMed ID: 10413320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
